STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines presented first‑line and combination trial data for daraxonrasib in advanced pancreatic cancer at the AACR meeting in San Diego.
- Revolution Medicines disclosed preclinical results for RM‑055, a catalytic KRAS inhibitor that can switch off the oncogenic protein.
- NCI director affirmed that the daraxonrasib data supports continued development and potential regulatory engagement.
Why it matters: Not enough in the article to say why this matters.
Ask SkimNews
